Author

Jan Endell

Observed names: Endell, Jan, J Endell, J. Endell

Observed institutions: Medigene (Germany), MorphoSys (Germany), German Cancer Research Center, University of Cologne, Kaplan Medical Center, Affimed Therapeutics (Germany), Ludwig-Maximilians-Universität München

ORCID: 0000-0002-9790-4414

Observed ORCID: 0000-0002-9790-4414

OpenAlex ID: A5079112201

Green Fluorescent Protein-Tagged Adeno-Associated Virus Particles Allow the Study of Cytosolic and Nuclear Trafficking

2005 · Kerstin Lux, Nico Goerlitz, et al. · Journal of Virology · 152

Combinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus

2005 · Luca Perabo, Jan Endell, et al. · The Journal of Gene Medicine · 136

Heparan Sulfate Proteoglycan Binding Properties of Adeno-Associated Virus Retargeting Mutants and Consequences for Their In Vivo Tropism

2006 · Luca Perabo, Daniela Goldnau, et al. · Journal of Virology · 133

Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma

2010 · Silke Wolterink, Gerhard Moldenhauer, et al. · Cancer Research · 69

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

2019 · Pedro Horna, Grzegorz Nowakowski, et al. · Blood · 56

α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma

2014 · Katharina Teiluf, Christof Seidl, et al. · Oncotarget · 49

PDF

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

2016 · Marc S. Raab, Manik Chatterjee, et al. · Blood · 39

The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo

2012 · Jan Endell, Rainer Boxhammer, et al. · Blood · 37

CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

2021 · Johannes Duell, Aleš Obr, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 26

PDF

Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide.

2015 · Rainer Boxhammer, Stefan Steidl, et al. · Journal of Clinical Oncology · 26

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

2023 · R. Leo Sakemura, Claudia Manriquez Roman, et al. · Blood · 25

MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds

2015 · Rainer Boxhammer, Johannes Weirather, et al. · Blood · 24

MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study.

2016 · Marc S. Raab, Manik Chatterjee, et al. · Journal of Clinical Oncology · 17

Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy

2022 · Jung Hyun Her, Dominik Pretscher, et al. · Cancer Immunology Immunotherapy · 13

PDF

Blocking T cell co-stimulation using a CD80 blocking small molecule reduces delayed type hypersensitivity responses in rhesus monkeys

2009 · K G Haanstra, J Endell, et al. · Clinical & Experimental Immunology · 13

PDF

Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro

2019 · Paulina Horvei, Reona Sakemura, et al. · Blood · 12

Macroporous silicon chips for laterally resolved, multi-parametric analysis of epithelial barrier function

2012 · Stefanie Michaelis, Christina E. Rommel, et al. · Lab on a Chip · 11

Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma.

2011 · J. Endell, C. Samuelsson, et al. · Journal of Clinical Oncology · 11

The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS

2025 · Nanni Schmitt, Jana-Julia Siegler, et al. · Nature Communications · 10

PDF

Synergistic in Vitro Activity of MOR202, a Human CD38 Antibody, in Combination with Pomalidomide

2014 · Jan Endell, Rainer Boxhammer, et al. · Blood · 10

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

2019 · Dimitrios Mougiakakos, Simon Voelkl, et al. · Blood · 9

Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro

2020 · Paulina Horvei, Reona Sakemura, et al. · Transplantation and Cellular Therapy · 8

Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells after Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data

2019 · Rainer Boxhammer, Frank Striebel, et al. · Blood · 8

Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

2016 · Wojciech Jurczak, Pier Luigi Zinzani, et al. · Blood · 8

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma

2023 · Maria Patra-Kneuer, Gaomei Chang, et al. · Frontiers in Immunology · 7

PDF

Works count: 51

Citation count: 926

H-index: 13

I10-index: 20